

Pioneering Healthcare Solution for Antimicrobial Resistance.
An opportunity to acquire a trailblazing solution for combating antimicrobial resistance and revolutionising clinical guidance access worldwide.
Please read on to discover more.
Who are we and why are we contacting you?
About us:
We are Orb - A specialist investment deal-flow company with offices in London and Geneva. We work with global businesses and investors to identify off-book acquisition and investment opportunities.Our core business is identifying opportunities where the acquirer/investor and the target companies can look to achieve a genuine win-win deal. We do this by working closely with our clients to understand which businesses will complement their growth strategy before identifying and reaching out to discuss the opportunity.
About this opportunity:
Antimicrobial resistance (AMR) is a growing global health threat, with 1.3 million people dying from antibiotic-resistant infections in 2019 alone. Traditional access to localised antimicrobial guidance has been inefficient, leading to overprescription of broad-spectrum antibiotics and a surge in drug-resistant pathogens.
The Solution
The business has revolutionised the way healthcare providers access and implement clinical guidance, policies, and procedures. First implemented at a UK University Hospital, where it led to a sustained reduction in high-risk broad-spectrum antibiotic prescriptions from 40% to 28%. The platform has since expanded to 75% of NHS Acute Hospitals and is now used in 13 different countries, totalling 170 medical organisations worldwide.
The Product
Offers a comprehensive and user-friendly Content Management System (CMS) for content editors, a mobile app for clinicians, and a web viewer for intranet access. The platform also includes a Decision Support Module (DSM) and a Patient Information Module (PIM), offering personalised drug regimens and patient-specific information, respectively.
Further Developments
The platform has evolved to manage a wide range of clinical guidance types and non-clinical documents such as policies and procedures. New modules, like the Import Bot and Governance Review Module (GRM), streamline content migration and management, making the product a one-stop-shop for healthcare organisations. The company has also developed an OPAT-Patient Management that supports nurses who are treating patients with antibiotics as outpatients, providing them access to a “Virtual Ward” where they can search and find current OPAT Patients, segment these patients into cohorts using a selection of pre-designed filters and update the patients’ record.The PMS service could be adapted to help manage the treatment of generic conditions rather than just patients with infectious diseases.
[In The UK, £250 million is available nationally to support the setup and development of Virtual Wards in 2023/24, on a match-funded basis]
The Opportunity
As a leader in combating AMR and improving clinical efficiency, the business presents a compelling acquisition opportunity for investors seeking a proven, scalable solution with significant growth potential in the global healthcare market.Introduction.
Meet Gail, Part of research team at Orb.
If you have any questions or would like a meeting to explore and understand your options, then please use the links below to contact us directly.
Key Summary
Expected deal-size ~ EV £4/5 million(GBP)
Addressing Global
AMR Challenges
Acquire a market-leading solution addressing the global challenge of antimicrobial resistance.
Efficient Clinical
Guidance Access
Tap into the rapidly expanding demand for efficient clinical guidance and patient information management.
Widespread
Adoption & Success
Leverage a proven platform adopted by 75% of NHS Acute Hospitals and 170 medical organisations across 13 countries.
Innovative
Product Suite
Benefit from an innovative product suite, including mobile apps, web viewers, and robust content management systems.
Significant
Growth Potential
Seize the potential for significant growth and expansion in the international healthcare market.
Proven Impact
on Patient Outcomes
Invest in a cutting-edge platform with a solid track record of reducing high-risk antibiotic prescriptions and improving patient outcomes.
Next steps.
1Book a meeting with our team.
Let our team introduce themselves, present the opportunity and understand a little more about your business.
(we and the client are happy to sign an NDA)
2Your business is reviewed.
Our team will review your business - If the business is a good fit, we will come back to you to arrange a direct introduction.

About Orb
Investment Risk
Products
Placement Agent
Investor Relations
Orb MCL. 2024
Orb MCL operates within the investment sector. We have conducted a thorough review of the Financial Conduct Authority (FCA) regulations based on the nature of our services and activities. While are not required to be authorised or regulated by the FCA, we use these guidelines to remain committed to upholding the highest standards of conduct and professionalism in all our operations.